Home > News > Ministry stays DGGI ban on Natco's generic cancer drug
January 11th, 2010
Ministry stays DGGI ban on Natco's generic cancer drug
Abstract:
Natco Pharma today said the government has stayed an order of the Drug Controller-General of India (DCGI) which had stopped the company from producing breast cancer drug Albupax after it failed a toxicity test.
"The government of India has stayed the suspension of Albupax manufacturing (product) licence. Natco would announce its future plans shortly," the pharma firm said in a filing to the BSE.
Albupax, a nanotechnology-based drug, is the first generic version of abraxane, originally manufactured originally by US-based Abraxis Bioscience. Abraxis had complained about the side effects of Natco's version of the medicine.
Source:
domain-b.com
Bookmark:
| Related News Press |
News and information
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Govt.-Legislation/Regulation/Funding/Policy
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Nanobiotechnology
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||